



(51) International Patent Classification:
C12P 19/34 (2006.01) C12N 15/86 (2006.01)
A61K 48/00 (2006.01)

(21) International Application Number:
PCT/US2021/061177

(22) International Filing Date:
30 November 2021 (30.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/120,190 01 December 2020 (01.12.2020) US

(71) Applicants: **RESEARCH INSTITUTE AT NATION-
WIDE CHILDREN'S HOSPITAL** [US/US]; 700
Children's Drive, Room W172, Columbus, OH 43205 (US).
**THE CYPRUS INSTITUTE OF NEUROLOGY AND
GENETICS** [CY/CY]; Iroon Avenue 6, Agios Dometios,
2371 (CY).

(72) Inventors: **HARPER, Scott Quenton**; 700 Children's Drive,
Columbus, OH 43205 (US). **KLEOPA, Kleopas**; 6
Iroon Avenue, Agios Dometios, 2371 (CY). **STAVROU,
Marina**; 6 Iroon Avenue, Agios Dometios, 2371 (CY).

(74) Agent: **NOLAND, Greta, E.**; Marshall, Gerstein & Borun
LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL
60606-6357 (US).


(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: PRODUCTS AND METHODS FOR INHIBITION OF EXPRESSION OF PERIPHERAL MYELIN PROTEIN-22

Figure 1

SEQ ID NO: 28



(57) Abstract: RNA interference-based methods and products for inhibiting the expression of a peripheral myelin protein-22 gene are provided. RNAs that inhibit the peripheral myelin protein-22 gene are provided as well as DMAs encoding the RNAs. Delivery vehicles such as recombinant adeno-associated viruses deliver DMAs encoding RNAs that inhibit the peripheral myelin protein-22 gene. The methods treat Charcot-Marie-Tooth Disease such as Charcot-Marie-Tooth Disease Type 1 A (CMT1A).

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*